{"id":"NCT02255552","sponsor":"Sarepta Therapeutics, Inc.","briefTitle":"Study of Eteplirsen in DMD Patients","officialTitle":"An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11-17","primaryCompletion":"2019-06-14","completion":"2019-06-14","firstPosted":"2014-10-02","resultsPosted":"2020-07-01","lastUpdate":"2021-01-25"},"enrollment":109,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Duchenne Muscular Dystrophy (DMD)"],"interventions":[{"type":"DRUG","name":"eteplirsen","otherNames":["AVI-4658","EXONDYS 51Â®"]}],"arms":[{"label":"Treated Group","type":"EXPERIMENTAL"},{"label":"Untreated Group","type":"NO_INTERVENTION"}],"summary":"The main objective of this study is to provide evidence of efficacy of eteplirsen (AVI-4658) in Duchenne muscular dystrophy (DMD) patients that are amenable to skipping exon 51. Additional objectives include evaluation of safety, biomarkers and the long-term effects of eteplirsen up to 96 weeks, followed by a safety extension (not to exceed 48 weeks).","primaryOutcome":{"measure":"Change From Baseline in the 6 Minute Walk Test (6MWT) Distance at Week 96","timeFrame":"Baseline, Week 96","effectByArm":[{"arm":"Eteplirsen 30 mg/kg","deltaMin":-117.91,"sd":128.488},{"arm":"Untreated Control Group (Non-exon 51 Amenable Participants)","deltaMin":-133.56,"sd":129.333}],"pValues":[]},"eligibility":{"minAge":"7 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":37,"countries":["United States"]},"refs":{"pmids":["31237898"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":79},"commonTop":["Headache","Vomiting","Cough","Nasopharyngitis","Back pain"]}}